Astrazeneca (LON:AZN) revealed an increase in annual revenue and revenue.
In its latest trading update, Pharma Giant said sales increased 9% to $18,879 million, with an overall revenue increase of 8% compared to the previous year.
CEO Pascal Soliot commented: Highlights of sales performance included further success in oncology and accelerated progress in Farxiga.
“Our pipeline is also excellent, expanding its potential beyond diabetes and heart failure with groundbreaking new data in chronic kidney disease, but acceptance of modulated obedience has been achieved with lupus aniflorumab. In the fight against Covid-19, we are working with Oxford University to launch a phase III trial for a combination of long-acting antibodies for prevention and treatment of Covid-19 for those who need immediate protection and those with weak immune systems.
“We continue to progress in line with expectations and maintain our annual guidance, supported by our sustainable growth strategy through innovation,” Soliot added.
AstraZeneca is working with Oxford University on the coronavirus vaccine. Yesterday he said he missed his target of delivering 30 million vaccine doses to UK authorities by the end of September. Instead, the company will provide 4 million doses.
“The predictions made in good faith at the time assumed that absolutely everything worked and there were no hiccups,” said Kate Bingham, chairman of the UK Vaccine Task Force.
Astrazeneca stock (LON: AZN) is trading at 8.550,00 (1205GMT).
